Table 1 Patient and tumor characteristics
| Â | n | % |
|---|---|---|
Total patients | 407 | Â |
Age mean (range) | 59.2 (28–90) |  |
Tumor location, right/left/bilateral | 228/172/7 | 56.0%/42.3%/1.7% |
NAC, yes/no | 125/282 | 30.7%/69.3% |
Total breast cancers | 414 | Â |
Type of surgery | Â | Â |
 Breast-conserving surgery | 164 | 39.6% |
 Modified radical mastectomy | 250 | 61.4% |
Histology | Â | Â |
 IDC | 373 | 90.1% |
 Others |  |  |
(Myxoid/ILC/apocrine/metaplastic) | 15/14/11/1 | 0.9% |
Molecular phenotype | Â | Â |
 Luminal A (ER + /HER2 − , Ki67 < 20%) | 148 | 35.7% |
 Luminal B (ER + /HER2 − , Ki67 ≥ 20%) | 120 | 29.0% |
 Luminal-HER2 (ER + /HER2 +) | 43 | 10.4% |
 HER2-positive (non-luminal) | 43 | 10.4% |
 Triple-negative | 60 | 14.5% |
Axillary lymph node metastasis | Â | Â |
 Present | 204 | 49.3% |
 Absent | 210 | 50.7% |
Diagnostic tool of axillary node | Â | Â |
 SLNB | 197 | 47.6% |
 ALND | 12 | 2.9% |
 SLNB and ALND | 59 | 14.3% |
 Aspiration cytology and ALND | 60 | 14.5% |
 Aspiration cytology and SLNB | 19 | 4.6% |
Aspiration cytology, SLNB, and ALND | 67 | 16.2% |
TNM Stage (I/II/III) | 140/217/57 | 33.8%/52.4%/13.8% |